Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Generic Paxil Priced At 7% Discount Following “At Risk” Launch

Executive Summary

Apotex is relying on a district court ruling of noninfringement in launching the first generic of GlaxoSmithKline's antidepressant Paxil (paroxetine)

You may also be interested in...



Zyprexa Patent Valid: Lilly’s Phase I Olanzapine Trials Were Not “Public Use”

Lilly's conduct of Phase I clinical trials for Zyprexa prior to applying for a composition/use patent did not constitute a prior "public use" that would render the patent invalid, an Indianapolis federal judge ruled April 14

Zyprexa Patent Valid: Lilly’s Phase I Olanzapine Trials Were Not “Public Use”

Lilly's conduct of Phase I clinical trials for Zyprexa prior to applying for a composition/use patent did not constitute a prior "public use" that would render the patent invalid, an Indianapolis federal judge ruled April 14

Mylan Takes “Authorized” Generics Fight To Congress, FTC, Courts

Mylan is taking its fight against "authorized" generics beyond FDA to Capitol Hill, the Federal Trade Commission and the federal courts

Related Content

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel